The Drug-Induced Respiratory Disease Website
Pleural effusion (uni or bilateral) (can accompany ILD induced by the drug)
Evidence level
low
Lone, isolated, free-flowing pleural effusion on imaging. See other forms of pleural effusions under Vb, d, e, g, h, i, m which may present similarly on imaging. The effusion can be uni- or bilateral. More often a lymphocyte-, mixed or neutrophil-rich exudate. At times the effusion is eosipophil-rich. Pleural effusion can be present with the acute clinical phase of severe drug-induced ILD (e.g. methotrexate lung; PMID 16840219). In general, pleural effusion in the context of drug-induced ILD or pulmonary edema is not tabulated under this heading. ANA-panel indicated to diagnose drug-induced lupus PMID 10424528
Publications
Hann CL, Burns TF, Dowlati A, Morgensztern D, Ward PJ, Koch MM, Chen C, Ludwig C, Patel M, Nimeiri H, Komarnitsky P, Camidge DR
Brief Report: A Phase 1 Study Evaluating Rovalpituzumab Tesirine (Rova-T) in Frontline Treatment of Patients With Extensive-Stage Small Cell Lung Cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2021 Jul 06;; — 2021 Jul 06
Johnson ML, Zvirbule Z, Laktionov K, Helland A, Cho BC, Gutierrez V, Colinet B, Lena H, Wolf M, Gottfried M, Okamoto I, van der Leest C, Rich P, Hung JY, Appenzeller C, Sun Z, Maag D, Luo Y, Nickner C, Vajikova A, Komarnitsky P, Bar J
Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage-SCLC: Results From the Phase 3 MERU Study.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2021 Apr 03;; — 2021 Apr 03
Malhotra J, Nikolinakos P, Leal T, Lehman J, Morgensztern D, Patel JD, Wrangle JM, Curigliano G, Greillier L, Johnson ML, Ready N, Robinet G, Lally S, Maag D, Valenzuela R, Blot V, Besse B
A Phase 1-2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2021 Feb 27;; — 2021 Feb 27
Morgensztern D, Besse B, Greillier L, Santana-Davila R, Ready N, Hann CL, Glisson BS, Farago AF, Dowlati A, Rudin CM, Le Moulec S, Lally S, Yalamanchili S, Wolf J, Govindan R, Carbone DP
Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2019 12 01;25;6958-6966 — 2019 12 01 — 6958-6966
Udagawa H, Akamatsu H, Tanaka K, Takeda M, Kanda S, Kirita K, Teraoka S, Nakagawa K, Fujiwara Y, Yasuda I, Okubo S, Shintani M, Kosloski MP, Scripture C, Tamura T, Okamoto I
Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2019 09;135;145-150 — 2019 09 — 145-150
Rudin CM, Pietanza MC, Bauer TM, Ready N, Morgensztern D, Glisson BS, Byers LA, Johnson ML, Burris HA, Robert F, Han TH, Bheddah S, Theiss N, Watson S, Mathur D, Vennapusa B, Zayed H, Lally S, Strickland DK, Govindan R, Dylla SJ, Peng SL, Spigel DR,
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.
The Lancet. Oncology 2017 01;18;42-51 — 2017 01 — 42-51